Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Cong WangDepartment of Gynecological Radiation Oncology, Zhengzhou University First Affiliated Hospital, No 1. Jianshe Road, Zhengzhou, 450000, China.ORCID 0000-0003-3501-2223
Lijun LiuDepartment of Rheumatology, Zhengzhou University First Affiliated Hospital, No 1. Jianshe Road, Zhengzhou, 450000, China.
Xia LiDepartment of Gynecological Radiation Oncology, Zhengzhou University First Affiliated Hospital, No 1. Jianshe Road, Zhengzhou, 450000, China.
Jia LeiDepartment of Gynecological Radiation Oncology, Zhengzhou University First Affiliated Hospital, No 1. Jianshe Road, Zhengzhou, 450000, China.
Yiqian LiDepartment of Gynecological Radiation Oncology, Zhengzhou University First Affiliated Hospital, No 1. Jianshe Road, Zhengzhou, 450000, China.
Zhibo ShenDepartment of Gynecological Radiation Oncology, Zhengzhou University First Affiliated Hospital, No 1. Jianshe Road, Zhengzhou, 450000, China.
Huirong ShiDepartment of Gynecology, Zhengzhou University First Affiliated Hospital, No 1. Jianshe Road, Zhengzhou, 450000, China.
Yan ChengDepartment of Gynecological Radiation Oncology, Zhengzhou University First Affiliated Hospital, No 1. Jianshe Road, Zhengzhou, 450000, China.ORCID 0009-0000-4363-8774
Funding
the key Research and development and promotion Special project (Science and Technology Research) of Henan Provincial Science and Technology Department in 2023 232102311037the Key scientific Research Project of Henan Provincial Colleges and Universities in 2022 22A320059
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
PD-1 inhibitor plus concurrent chemoradiotherapy for high-risk locally advanced cervical cancer. · full record | OpenQuestion